Buy Zokinvy (lonafarnib) online – Zokinvy (lonafarnib) for sale
What is Zokinvy (lonafarnib) for?
Zokinvy (lonafarnib) is an farnesyltransferase inhibitor indicated to reduce the risk of death due to:
- Adults and children aged 12 months or older with Hutchinson-Gilford Progeria Syndrome (HGPS), who have a certain body surface area
- Adults and children 12 months of age or older with certain types of Progeroid Laminopathies, who have a certain body surface area
Zokinvy (lonafarnib) is not for use in people with non-HGPS Progeroid Syndromes or with Progeroid Laminopathies that are processing-proficient.[1]
It is available in capsule form containing 50 mg of 75 mg lonafarnib.[1]
How does Zokinvy (lonafarnib) work?
Patients with HGPS and progeroid laminopathies experience a buildup of broken progerin or progerin-like protein in cells. Progerin is a defective version of the protein Lamin A, which is important for the protection of cells and prolongation of cellular lifespan.[2,3]
Lonafarnib is a farnesyltransferase inhibitor. It helps prevent the buildup of defective progerin or progerin-like protein. Farnesyltransferase is an enzyme that is involved in the adjustment of proteins in a process called prenylation.[2,3]
Lonafarnib inhibits prenylation of progerin, thereby preventing the production and buildup of broken progerin.[2,3]
Where has Zokinvy (lonafarnib) been approved?
Zokinvy (lonafarnib) was approved for the treatment of patients with Progeria and Progeroid Laminopathies by:[4]
- The Food and Drug Administration (FDA), on November 20, 2020.
It is the first FDA-approved medication for these diseases.[4]
Zokinvy (lonafarnib) received Orphan Drug designation by the FDA and the European Medicines Agency (EMA), which is awarded to encourage development of drugs against rare diseases. Zokinvy (lonafarnib) also received Priority Review and Breakthrough Therapy Designation. In addition, the medicine received a rare pediatric disease priority review voucher, which is intended to promote development of new medicines to prevent and treat rare diseases in children.[4]
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Zokinvy (lonafarnib) taken?
The standard dosage is:[1]
- Based on body size (height and weight). The treating doctor will determine the dose to be taken.
Zokinvy (lonafarnib) capsules should be taken by mouth (orally) 2 times a day, with morning and evening meals. The capsules should be swallowed whole, with plenty of water.[1]
If the patient is unable to swallow the capsule whole, see the detailed instructions in the official prescribing information. The contents of the capsules can be mixed with either Ora Blend SF, Ora-Plus, orange juice, or applesauce. The freshly prepared mixture should be taken within about 10 minutes of mixing.[1]
Zokinvy (lonafarnib) cannot be taken with any juice that contains grapefruit or Seville oranges (also called bitter or sour oranges).[1]
Because it can interact with other medicines, Zokinvy (lonafarnib) should not be taken together with a strong or moderate CYP3A inhibitor or inducer, as well as midazolam and certain cholesterol-lowering medications.[1]
Complete information about Zokinvy (lonafarnib) dosage, administration and possible drug interactions can be found in the official prescribing information.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Zokinvy (lonafarnib)?
Common adverse reactions
The most common side effects (≥10% of patients) listed in the prescribing information include:[1]
- Vomiting
- Diarrhea
- Infection
- Nausea
- Decreased appetite
- Tiredness
- Upper respiratory tract infection
- Stomach-area (abdominal) pain
- Muscle and joint (musculoskeletal) pain
- Electrolyte abnormalities
- Decreased weight
- Headache
- Myelosuppression
- Increased liver enzyme blood test results
- Decreased blood bicarbonate
- Cough
- Increased blood pressure (hypertension)
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:[1]
- Severe kidney problems
- Eye problems
Use in a specific population
Zokinvy (lonafarnib) may cause fertility problems in men and women, which may affect your ability to have children. Talk to your doctor if you have concerns about fertility.[1]
The medicine can cause fetal harm when administered to a pregnant woman, it is advised to avoid pregnancies and breastfeeding.[1]
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.[1]
References
1. Full prescribing information [FDA]: Zokinvy (lonafarnib) [PDF]
Eiger BioPharmaceuticals, Nov 21, 2020
2. Targeting Protein Prenylation in Progeria
Young SG, Sci Transl Med., Feb 6, 2013
3. Progeria and Progeroid Laminopathies
Eiger BioPharmaceuticals, cited on Nov 26, 2020
4. FDA approves new treatment for adults with partial-onset seizures
FDA press release, Nov 21, 2020
Reviews
There are no reviews yet.